176 related articles for article (PubMed ID: 24132482)
1. Oncolytic adenovirus characterization: activity and immune responses.
Gil-Hoyos R; Miguel-Camacho J; Alemany R
Methods Mol Biol; 2014; 1089():117-32. PubMed ID: 24132482
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
3. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
Hoffmann D; Wildner O
BMC Biotechnol; 2006 Aug; 6():36. PubMed ID: 16887042
[TBL] [Abstract][Full Text] [Related]
4. Species D Adenoviruses as Oncolytic Viral Vectors.
Bullard BL; Corder BN; Weaver EA
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291224
[TBL] [Abstract][Full Text] [Related]
5. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.
Wold WS; Toth K
Adv Cancer Res; 2012; 115():69-92. PubMed ID: 23021242
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenoviruses: design, generation, and experimental procedures.
Davydova J; Yamamoto M
Curr Protoc Hum Genet; 2013 Jul; Chapter 12():Unit 12.14. PubMed ID: 23853080
[TBL] [Abstract][Full Text] [Related]
7. Chapter four--Design of improved oncolytic adenoviruses.
Alemany R
Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
[TBL] [Abstract][Full Text] [Related]
8. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.
Dong W; van Ginkel JW; Au KY; Alemany R; Meulenberg JJ; van Beusechem VW
Hum Gene Ther; 2014 Oct; 25(10):897-904. PubMed ID: 25093639
[TBL] [Abstract][Full Text] [Related]
9. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.
Xiang ZQ; Yang Y; Wilson JM; Ertl HC
Virology; 1996 May; 219(1):220-7. PubMed ID: 8623532
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K
Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920
[TBL] [Abstract][Full Text] [Related]
11. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
12. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer.
Ma S; Qu W; Mao L; Zhu Z; Jia L; Zhao L; Zheng X
Oncol Rep; 2012 May; 27(5):1443-50. PubMed ID: 22294034
[TBL] [Abstract][Full Text] [Related]
14. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
15. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
16. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
17. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
18. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
[TBL] [Abstract][Full Text] [Related]
19. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
Ilett E; Kottke T; Donnelly O; Thompson J; Willmon C; Diaz R; Zaidi S; Coffey M; Selby P; Harrington K; Pandha H; Melcher A; Vile R
Mol Ther; 2014 Oct; 22(10):1851-63. PubMed ID: 24957982
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.
Koski A; Bramante S; Kipar A; Oksanen M; Juhila J; Vassilev L; Joensuu T; Kanerva A; Hemminki A
Mol Ther; 2015 Oct; 23(10):1641-52. PubMed ID: 26156245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
